Delivery Order SPE2DB20D1109-SPE2DB25FP68H
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,604.51. This is a firm fixed price delivery order with an ultimate completion date of August 15, 2025, executed under a competitive procurement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a contract ceiling value of $2,679.66 and an ultimate completion date of May 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,406.00. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside, competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,070.57. This non-set-aside, competitively awarded contract reflects the firm fixed-price delivery model that characterizes federal pharmaceutical procurement through the DLA's medical supply chain. The order is scheduled for ultimate completion on June 26, 2025, and will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $3,132.65. This is a firm fixed-price delivery order with an ultimate completion date of August 1, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $8,385.72. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 28, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single-unit pharmaceutical delivery under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $5,060.88. This competitively awarded, non-set-aside delivery order is scheduled for completion by September 18, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The contract follows a firm fixed price structure typical of DLA pharmaceutical procurement for...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP68HDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $3,904.42. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete effectively in federal pharmaceutical procurement. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen supplies a broad range of medications and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare customers. The NovoLog insulin product reflects the company's role in supplying critical diabetes management medications essential to military medical readiness and veteran healthcare services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 9/3/25 |